Royalty Pharma (RPRX) Q2 FY26 earnings call: guidance and Q&A

How does increased pharma M&A affect deal structure flexibility (equity vs. debt)? Does the improved credit rating or potential rate decreases bias more capital deployment?

Royalty Pharma has significant financial flexibility to partner in M&A opportunities. The company is agnostic to the rate environment, having deployed capital successfully in both rising and falling rate scenarios, focusing on generating returns in excess of its cost of capital while maintaining its investment-grade rating.

“we truly are agnostic to the rate environment. Rates over a couple of years were rising. We deployed a lot of capital, generated great returns in excess of our cost of capital. to the extent that rates start going down, we still feel like we can deploy capital and generate great returns.”

asked by Geoffrey Meacham · answered by Terrance Coyne

What are the implications of the Cardio Transform data for Amvuttra's forward outlook? Can you provide an update on the synthetic royalty opportunity and board openness?

Royalty Pharma is well-positioned with two ATTR amyloidosis investments. The Cardio Transform outcome, while unfortunate for patients, removes a near-term competitor for Amvuttra, and any delays for Alnylam's follow-on product would benefit Amvuttra. The synthetic royalty opportunity remains exciting, with significant growth and clear advantages, though it still represents a small portion of biopharma funding.

“it is unique in the sense that it is positioned in some ways to drive at least some benefit from the unfortunate outcome of cardio transform, which we certainly are never sort of welcome seeing trials sale for patients, but specifically with Amvuttra certainly does take away a near-term competitor.”

asked by Terence Flynn · answered by Marshall Urist

Given Royalty Pharma's growth and team, is there interest in leaning more into development-stage assets for potentially higher returns? What are the initial learnings and opportunities in the China market?

The 65%/35% split between approved and unapproved investments has been consistent, but the unapproved portion of invested capital could trend up to mid-to-high teens without significantly increasing overall portfolio risk. China is an early-stage but attractive long-term opportunity, with innovation driving out-licensing and royalty creation, often with offshore IP and US/EU-governed contracts.

“The amount invested in unapproved, as you can see, is relatively low. It's about 12%. That number could trend up to mid- to high teens. And it would still be a portfolio that has relatively low risk.”

asked by Christopher Schott · answered by Pablo Legorreta

What caused the low operating costs in Q2 and the expected increase in H2? Pablo, why do you believe Royalty Pharma is irreplicable, even with significant capital?

Operating costs reflect internalization synergies, with some seasonality causing H2 to be higher than H1. Pablo explained that Royalty Pharma's irreplicability stems from its scale, low cost of capital, superb team, and, most importantly, its unique, diversified portfolio of one-of-a-kind royalty assets that took decades to assemble and cannot be spontaneously recreated.

“It's a portfolio that produces $3.2 billion last year of recurring revenue, predictable recurring revenue from a very well-diversified portfolio of products and its top products marketed by top companies. It took us over a decade to assemble that portfolio.”

asked by Michael Nedelcovych · answered by Pablo Legorreta

What are the latest IRR expectations for development-stage versus approved assets? What level of MACE risk reduction for pelacarsen would be clinically meaningful, especially with high baseline Lp(a)?

Unlevered IRR expectations are high single to low double-digits for approved products (typically higher end) and in the teens for unapproved products. Levered returns for shareholders are significantly higher. For pelacarsen, management defers to Novartis's expectations for clinical relevance, acknowledging that the trial will provide important learnings on Lp(a) and patient benefit.

“For things that are unapproved, our IRR expectations are above that. So in the teens, and that can range depending on the specifics of the product at this stage, the risk profile, the counterparty, all of those things.”

asked by Ashwani Verma · answered by Marshall Urist

How do you handicap cliramitug's Phase III success given Phase I biomarkers and unproven mechanism? How do you prevent adverse selection in R&D co-funding, ensuring you fund exciting assets?

Cliramitug's enthusiasm is based on intriguing biomarker data (amyloid clearance, NP proBNP), historical translation of biomarker data to positive CV outcomes in ATTR, and evidence of amyloid depletion driving clinical benefit in other diseases. For R&D co-funding, Royalty Pharma emphasizes funding only the most exciting assets, maintaining a high bar and discipline, as evidenced by recent deals with Teva and J&J.

“And we really emphasized in every situation that we want to fund their most exciting assets. And that is a key criteria for us, and we're very disciplined about that.”

asked by Michael DiFiore · answered by Marshall Urist

How is Royalty Pharma tracking towards its $4.7 billion portfolio receipts target for 2030, and when might it be updated? What emerging therapeutic areas are catching your interest?

Royalty Pharma feels good about tracking towards the $4.7 billion 2030 guidance, but it's too early to consider updates. The team is structured to be broad and generalist, open to analyzing any therapeutic area or product globally, without a top-down portfolio perspective, allowing them to capitalize on opportunities as they arise.

“So on our long-term guidance of $4.7 billion or more on the top line by 2030, we feel really good about where we're tracking. I think it's -- really focused on that guidance at our Investor Day in September. So it's probably still early to be thinking about any changes there, but we feel like we're tracking really well.”

asked by Asad Haider · answered by Terrance Coyne

What are your thoughts on US policy risk (Coins Act, Ben's Act) regarding China, and does it affect your patient approach? Is it realistic to expect milestones to be a more meaningful contributor in H2?

Royalty Pharma is monitoring US policy risks regarding China but remains committed to the opportunity, noting that existing royalty agreements with Western multinationals are already substantial. Royalties are also distinct from equity, making them less susceptible to certain restrictions. Milestones are still expected to be around $60 million for the full year, implying no significant increase in H2.

“The bottom line is we're very committed to the opportunity there. We've hired Ken Sun, super excited about that hire and building out that opportunity. We'll continue to monitor the situation here in Washington but it's important to have a local presence there and the opportunity, I would note that the opportunity already exists because the last 5 or 6 years of all the out-licensing the Western multinationals, there is a substantial number of Royalty agreements that already are in place regardless of what happens in Washington.”

asked by Jason Gerberry · answered by Christopher Hite